Shares of OraSure Technologies OSUR fell in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share were down 50.00% over the past year to $0.03, which missed the estimate of $0.07.
Revenue of $62,855,000 higher by 26.55% year over year, which beat the estimate of $57,290,000.
Looking Ahead
OraSure Sees Q1 Net Sales $55M-$60M
Conference Call Details
Date: Mar 01, 2021
Time: 05:00 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/95z6s52d
Technicals
Company's 52-week high was at $19.75
Company's 52-week low was at $5.23
Price action over last quarter: down 13.77%
Company Description
OraSure Technologies Inc is engaged in the development, manufacturing, and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its reportable segments are OSUR and DNAG. The OSUR business, consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices, DNAG segment manufacture and sell kits that are used to collect, stabilize, transport and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome and animal genetics markets. It generates a majority of its revenue from the OSUR business segment.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.